Temporal lobe central benzodiazepine binding in unilateral mesial temporal lobe epilepsy.

PET-demonstrated decreases in [11C]flumazenil binding occur in anterior mesial temporal structures on the side of epileptogenesis in unilateral mesial temporal lobe epilepsy. We performed quantitative autoradiography on anterior mesial and lateral temporal specimens from 11 subjects with unilateral mesial temporal lobe epilepsy and six neurologically normal controls to identify the predominant in vitro correlates of the decreased [11C]flumazenil binding. In anterior mesial temporal regions exhibiting the greatest neuronal cell loss, decreases in agonist and antagonist binding to type 1 and 2 (central) benzodiazepine binding sites were highly correlated with neuronal cell counts. Cell loss and decreased binding were particularly prominent in the lateral portion of hippocampal region CA1, adjacent to CA2. Lateral temporal central benzodiazepine binding was diffusely increased, achieving statistical significance in cortical laminae V and VI. These findings suggest that the predominant source of PET-demonstrated decreases in [11C]flumazenil binding in mesial temporal epilepsy is hippocampal sclerosis, rather than down-regulation of central benzodiazepine binding sites on surviving hippocampal neurons.

Quantitative autoradiography of [3H]t-butylbicycloorthobenzoate binding to the gamma-aminobutyric acid receptorA complex.

The picrotoxinin ligand [3H]t-butylbicycloorthobenzoate ([3H] TBOB) was evaluated as an autoradiographic ligand to study gamma-aminobutyric acidA (GABAA) receptors. Specific [3H]TBOB binding was approximately 80% of total binding, was saturable and identified a single population of binding sites with regional Kd approximating 30 nM. [3H]TBOB binding was inhibited by picrotoxin, isoguvacine and pregnenolone sulfate. The benzodiazepines clonazepam and zolpidem produced complex effects with concentration-dependent inhibition and enhancement of [3H] TBOB binding. [3H]TBOB binding was regionally heterogeneous with high levels of binding in globus pallidus and layer IV of neocortex, intermediate levels of binding in other neocortical laminae and the cerebellar molecular layer and low levels of binding in the striatum and septum. The regional distribution of [3H]TBOB binding correlated poorly with the regional distribution of [3H]muscimol binding, somewhat better with the regional distribution of [3H]flunitrazepam binding and [35S]t-butylbicyclophosphorothionate binding and quite well with the regional distribution of [3H]zolpidem binding. [3H]TBOB binding site autoradiography is a convenient technique for studying GABAA receptor pharmacology in a regionally specific manner.

Zinc inhibition of t-[3H]butylbicycloorthobenzoate binding to the GABAA receptor complex.

The effect of Zn2+ on t-[3H]butylbicycloorthobenzoate ([3H]TBOB) binding to the GABAA receptor complex was studied autoradiographically in rat brain. Zn2+ inhibited [3H]TBOB binding in a dose-dependent manner at physiological concentrations. Saturation analysis revealed noncompetitive inhibition in various brain regions. The inhibitory effect of Zn2+ had regional heterogeneity; regions showing the greatest inhibition of [3H]TBOB binding were cortical laminae I-III, most areas of hippocampus, striatum, septum, and cerebellar cortex. Regions with relatively less inhibition of [3H]TBOB binding included cortical laminae V-VI, thalamus, superior colliculus, inferior colliculus, and central gray matter. The effect of Zn2+ and those of other GABAA ligands, such as benzodiazepines, bicuculline, isoguvacine, and picrotoxin, on [3H]TBOB binding seemed to be additive. Ni2+, Cd2+, and Cu2+ also inhibited [3H]TBOB binding with a regional heterogeneity similar to that produced by Zn2+. These results are consistent with Zn2+ acting at the previously detected recognition site on the GABAA receptor complex, distinct from the picrotoxin, GABA, and benzodiazepine sites. The regional heterogeneity of the Zn2+ effect may reflect differential regional distribution of GABAA receptor subtypes among brain regions. Other divalent cations probably act at the Zn2+ binding site.

Unchanged [3H]MK-801 binding and increased [3H]flunitrazepam binding in turtle forebrain during anoxia.

In order to determine if functional changes in N-methyl-D-aspartate receptors and GABAA receptors play a role in the remarkable anoxia tolerance of freshwater turtle brain, we used autoradiographic techniques to assay [3H]MK-801 and [3H]flunitrazepam binding in turtle forebrain after turtles had been subjected to anoxia for 2 or 6 h. The effects of glutamate, glycine, competitive N-methyl-D-aspartate antagonists, glycine antagonists, polyamines, magnesium, and zinc on [3H]MK-801 binding were the same in anoxic and control turtle forebrains. These results indicate that NMDA receptor regulation plays no role in the adaptive responses to anoxia in turtle brain. In contrast, [3H]flunitrazepam binding was significantly increased in the anoxic dorsal cortex and striatum. The most parsimonious explanation for elevated benzodiazepine receptor binding is that the rise in extracellular GABA levels known to accompany anoxia enhances benzodiazepine receptor affinity. It is possible, however, that GABAA receptor upregulation during anoxia increases the effectiveness of the inhibitory action of released GABA and contributes to the anoxia tolerance of turtles.

Cerebellar excitatory and inhibitory amino acid receptors in multiple system atrophy.

We studied excitatory and inhibitory amino acid binding sites autoradiographically in control and multiple system atrophy (MSA) cerebella. Within the dentate nucleus (DN) of MSA specimens, we found a significant increase in the level of GABAA, benzodiazepine, and metabotropic binding sites compared with controls. In the granule cell layer, kainate, N-methyl-D-aspartate, and GABAA binding sites were all decreased significantly in MSA specimens compared with controls. In the molecular layer of MSA cerebellum, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate binding sites were decreased significantly compared with controls. Cerebellar cortical binding site decreases are likely due to Purkinje and granule cell loss. The increase of binding site levels in DN of MSA specimens may represent receptor up-regulation reflecting loss of descending inhibitory Purkinje cell and ascending excitatory afferents to the DN.

Regionally distinct N-methyl-D-aspartate receptors distinguished by quantitative autoradiography of [3H]MK-801 binding in rat brain.

Quantitative autoradiography of [3H]MK-801 binding was used to characterize regional differences in N-methyl-D-aspartate (NMDA) receptor pharmacology in rat CNS. Regionally distinct populations of NMDA receptors were distinguished on the basis of regulation of [3H]MK-801 binding by the NMDA antagonist 3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP). CPP inhibited [3H]MK-801 binding in outer cortex (OC) and medial cortex (MC) with apparent Ki values of 0.32-0.48 microM, whereas in the medial striatum (MS), lateral striatum (LS), CA1, and dentate gyrus (DG) of hippocampus, apparent Ki values were 1.1-1.6 microM. In medial thalamus (MT) and lateral thalamus (LT) the apparent Ki values were 0.78 microM. In the presence of added glutamate (3 microM), the relative differences in apparent Ki values between regions maintained a similar relationship with the exception of the OC. Inhibition of [3H]MK-801 binding by the glycine site antagonist 7-chlorokynurenic acid (7-ClKyn) distinguished at least two populations of NMDA receptors that differed from populations defined by CPP displacement. 7-ClKyn inhibited [3H]MK-801 binding in OC, MC, MS, and LS with apparent Ki values of 6.3-8.6 microM, whereas in CA1, DG, LT, and MT, Ki values were 11.4-13.6 microM. In the presence of added glycine (1 microM), the relative differences in apparent Ki values were maintained. Under conditions of differential receptor activation, regional differences in NMDA receptor pharmacology can be detected using [3H]MK-801 binding.

Inhibitory and excitatory amino acid neurotransmitter binding sites in cynomolgus monkey (Macaca fascicularis) cervical spinal cord.

Autoradiography of inhibitory and excitatory amino acid neurotransmitter binding sites in the cervical spinal cord of M. fascicularis spinal cord revealed inhomogeneous distribution of all binding sites in spinal gray matter. Quisqualate-sensitive [3H]glutamate binding, [3H]MK-801 binding, benzodiazepine binding, kainate binding, and GABAB binding had highest levels in the superficial layers of the dorsal horn (laminae 1 and 2) and substantially lower levels in other laminae. [3H]Strychnine binding was more uniformly distributed throughout all laminae with highest levels in the superficial layers of the dorsal horn. These results are similar to those found in other mammals.

Excitatory amino acid, GABA(A), and GABA(B) binding sites in human striate cortex.

Receptor autoradiography was used to study the laminar distribution of excitatory amino acid, GABA(A), and GABA(B) binding sites in human striate cortex. Binding sites for all these receptor subtypes were found within striate cortex, but there were marked differences in the laminar distribution of binding sites. NMDA binding sites were most dense in layers 1-4C, with highest density in layer 4C and lower levels in layers 5 and 6. Among non-NMDA binding sites, alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid binding sites had highest levels in layers 1-3, intermediate levels in layers 5 and 6, and lowest levels in layers 4B and 4C. Kainate and metabotropic binding sites were more uniformly distributed across cortical laminae, with a trend toward highest kainate binding in layers 5 and 6. GABA(A)/benzodiazepine binding sites had highest levels in layers 2, 3, and 4C, with intermediate levels in 4B and lowest levels in layers 1, 5, and 6. GABA(B) binding sites were uniformly distributed across laminae. There was no evidence of a "columnar" or "blob" pattern of any binding site within any of the laminae. With the exception of kainate, metabotropic excitatory amino acid, and GABA(B) binding sites, the laminar distribution of binding sites within striate cortex was different than that seen in adjacent visual cortex.

Excitatory and inhibitory amino acid neurotransmitter binding sites in the cerebellar cortex of the pigeon (Columba livia).

We used receptor autoradiography to determine the distribution of excitatory and inhibitory amino acid neurotransmitter binding sites in the cerebellar cortex of the pigeon (Columba livia). alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid, kainate and metabotropic binding sites had highest levels in the molecular layer. N-methyl-D-aspartate binding sites, assayed with both [3H]glutamate under selective conditions and with [3H]glycine binding to the associated strychnine-insensitive glycine site, had highest levels in the granule cell layer. There was little specific binding of the non-competitive N-methyl-D-aspartate antagonist, [3H]MK-801. The level of gamma-aminobutyric acid (GABA)-A binding sites was higher than GABA-B binding sites in both molecular and granule cell layers with the highest level of GABA-A sites in the granule cell layer. The highest level of GABA-B binding sites was in the molecular layer. [3H]Flunitrazepam binding levels were approximately the same in both molecular and granule cell layers. With the exception of kainate binding sites, the distribution of binding sites was identical to that seen in the cerebellar cortex of mammals. Our results support the concept that the chemoarchitecture of the cerebellar cortex has been conserved in the course of vertebrate evolution.

2,4,5-Trihydroxyphenylalanine (6-hydroxy-dopa) displaces [3H]AMPA binding in rat striatum.

Excitatory amino acid (EAA) receptor-mediated events have recently been implicated in dopaminergic mechanisms of neurotoxicity. 2,4,5-Trihydroxyphenylalanine (6-hydroxy-DOPA, TOPA), the ortho-hydroxylated derivative of the dopamine precursor 2,4-dihydroxyphenylalanine (L-DOPA), has recently been reported to have neurotoxic properties which are blocked by CNQX, a specific antagonist of the AMPA class of non-N-methyl-D-aspartate (non-NMDA) EAA receptors. We report here that 6-hydroxy-DOPA is a selective displacer of [3H]AMPA binding in rodent brain. 6-Hydroxy-DOPA was as potent as kainate in displacing [3H]AMPA binding, with an IC50 value of 32 microM. Ineffective displacers of [3H]AMPA binding included dopamine, 6-hydroxydopamine, L-DOPA, D-DOPA, carbidopa, DOPAC, beta-methylamino-L-alanine, 2,4-dihydroxyphenylacetyl-L-asparagine, homogentisic acid, 2,4-dihydroxyphenylacetic acid, amantadine, and threo-DOPS. 6-Hydroxy-DOPA (100 microM) also displaced 20% of [3H]kainate binding, but did not displace binding to NMDA, phencyclidine (PCP), or dopaminergic (D1 and D2) receptors. These data raise the possibility that 6-hydroxy-DOPA or another abnormal metabolite of L-DOPA could act as an excitotoxic agent via action at AMPA receptors. Given that non-NMDA receptors are postulated to play a role in neurotoxic events, these data provide an additional mechanism via which EAA receptor-mediated events could produce neurodegeneration in areas of brain with dopaminergic innervation.

Excitatory and inhibitory amino acid binding sites in human dentate nucleus.

Autoradiography of excitatory and inhibitory amino acid binding sites in human dentate nuclei indicated virtually no binding to N-methyl-D-aspartate (NMDA) or gamma-aminobutyric acidB (GABAB) binding sites, and a low density of kainate binding sites. alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid, metabotropic-quisqualate, benzodiazepine, and gamma-aminobutyric acidA (GABAA) binding sites were present in moderate abundance. Our NMDA results differ from those found previously in rodents. GABAA receptors are probably the primary mediators of inhibitory neurotransmission and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid and metabotropic-quisqualate receptors are probably the primary mediators of excitatory neurotransmission within the human deep cerebellar nuclei.

Regional distribution and properties of [3H]MK-801 binding sites determined by quantitative autoradiography in rat brain.

[3H]MK-801 binding in rat brain was characterized using a quantitative autoradiographic binding assay. [3H]MK-801 binding (5 nM) reached equilibrium by 120 min at 23 degrees C. [3H]MK-801 appeared to label a single high affinity site with an affinity constant of approximately 11 nM. [3H]MK-801 binding was heterogeneously distributed throughout the brain with the following order of binding densities: hippocampal formation greater than cortical areas greater than striatum greater than thalamus. Competitive N-methyl-D-aspartate antagonists, DL-2-amino-5-phosphonopentanoic acid, DL-2-amino-7-phosphonoheptanoic acid, 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid, and cis-4-phosphonomethyl-2-piperidine carboxylic acid, inhibited [3H]MK-801 binding. Glycine antagonists, 7-chlorokynurenic acid and kynurenic acid, also inhibited [3H]MK-801 binding. Furthermore, the inhibition of [3H]MK-801 binding by the quinoxalinedione compounds 6-cyano-7-nitroquinoxaline-2,3-dione and 6,7-dinitroquinoxaline-2,3-dione was reversed by glycine. [3H]MK-801 binding was also inhibited by zinc ions [3H]MK-801 binding was enhanced by glycine or N-methyl-D-aspartate. These results demonstrate that [3H]MK-801 can be used in a quantitative autoradiographic assay as a functional probe for the N-methyl-D-aspartate receptor complex.

Excitatory amino acidergic pathways and receptors in the basal ganglia.

The striatum receives the majority of excitatory amino acidergic input to the basal ganglia from neocortical and allocortical sources. The subthalamic nucleus and the substantia nigra also receive excitatory amino acidergic inputs from neocortex. The subthalamic nucleus, which has prominent projections to the pallidum and nigra, is the only known intrinsic excitatory amino acidergic component of the basal ganglia. Possible excitatory amino acidergic inputs reach the basal ganglia from the intralaminar thalamic nuclei and the pedunculo-pontine nucleus. The striatum is richly endowed with all subtypes of excitatory amino acid receptors and these appear to be inhomogeneously distributed within the striatal complex. The non-striatal nuclei contain lesser levels of excitatory amino acid receptors and the relative proportion of these receptors varies between nuclei. The presence of high densities of excitatory amino acid receptors is a phylogenetically conserved feature of the striatum and its non-mammalian homologues. In Huntington's disease, there is substantial depletion ofα-amino-3-hydroxy-5-methylisoxazole-4-propionic acid, N-methyl-D-aspartate, and kainate receptors within the striatum. In Parkinson's disease substantia nigra, there is significant loss of N-methyl-D-aspartate andα-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.